key: cord-0872005-iisoa9tk
authors: Ferrando, Stephen J.; Dornbush, Rhea; Lynch, Sean; Shahar, Sivan; Klepacz, Lidia; Karmen, Carol L.; Chen, Donald; Lobo, Stephen A.; Lerman, Dania
title: Neuropsychological, medical and psychiatric findings after recovery from acute COVID-19: A cross-sectional study
date: 2022-01-25
journal: J Acad Consult Liaison Psychiatry
DOI: 10.1016/j.jaclp.2022.01.003
sha: 9f79ea3b705360bcd4e1db628c85b89fefac3a02
doc_id: 872005
cord_uid: iisoa9tk

BACKGROUND: This study describes neuropsychological, medical, psychiatric and functional correlates of cognitive complaints experienced after recovery from acute COVID-19 infection. METHODS: Sixty participants underwent neuropsychological (NP), psychiatric, medical, functional, and quality of life assessments 6-8 months after acute COVID-19. Those seeking care cognitive complaints in a post-COVID-19 clinical program for Post-Acute Symptoms of COVID-19 (PASC) (Clinical Group, N=32) were compared to those recruited from the community who were not seeking care (Non-Clinical, N=28). A subset of participants underwent serological testing for pro-inflammatory cytokines C-Reactive Protein, Interleukin-6, and Tumor Necrosis Factor-α in order to explore correlations with neuropsychological, psychiatric and medical variables. OUTCOME: For the entire sample, 16 (27%) had extremely low test scores (< 2(nd) %ile on at least 1 NP test). The Clinical Group with cognitive complaints scored lower than age-adjusted population norms in tests of attention, processing speed, memory, and executive function, and significantly more scored in the extremely low range than the Non-Clinical Group (38% vs. 14%, p<0.04). The Clinical Group also reported higher levels of depression, anxiety, fatigue, PTSD and functional difficulties and lower quality of life. In logistic regression analysis, scoring in the extremely low range was predicted by acute COVID-19 symptoms, current depression score, number of medical comorbidities and subjective cognitive complaints in the areas of memory, language, and executive functions. IL-6 correlated with acute COVID symptoms, number of medical comorbidities, fatigue, and measures of executive function. CRP correlated with current COVID symptoms, depression score and, inversely, with quality of life. CONCLUSION: Results suggest the existence of extremely low neuropsychological test performance experienced by some individuals months after acute COVID-19 infection, affecting multiple neurocognitive domains. This extremely low neuropsychological test performance is associated with worse acute COVID-19 symptoms, depression, medical comorbidities, functional complaints, and subjective cognitive complaints. Exploratory correlations with pro-inflammatory cytokines support further research into inflammatory mechanisms and viable treatments.

community who were not seeking care (Non-Clinical, N=28). A subset of participants underwent 48 serological testing for pro-inflammatory cytokines C-Reactive Protein, Interleukin-6, and Tumor 49

Necrosis Factor-α in order to explore correlations with neuropsychological, psychiatric and 50 medical variables. 51

Outcome: For the entire sample, 16 (27%) had extremely low test scores (< 2 nd %ile on at least 1 52 NP test). The Clinical Group with cognitive complaints scored lower than age-adjusted 53 population norms in tests of attention, processing speed, memory, and executive function, and 54 significantly more scored in the extremely low range than the Non-Clinical Group (38% vs. 14%, 55 p<0.04). The Clinical Group also reported higher levels of depression, anxiety, fatigue, PTSD 56 and functional difficulties and lower quality of life. In logistic regression analysis, scoring in the 57 extremely low range was predicted by acute COVID-19 symptoms, current depression score, Status Examination, and few employed formal neuropsychologica l testing (22). In a longer term 108 follow-up study, Pilotto et al. (2020) Participants met with study assessors (SL, SS), who were trained to perform and score the 151 assessment battery and were supervised by the study PI (SF) and co-PI (RD), the latter a board-152 certified Neuropsychologist. Participants were compensated $40 for their time. well as at the time of the study appointment was determined by score on an instrument adapted 161 from published CDC COVID-19 symptoms, assessing severity (absent, mild, moderate, severe) 162 on 11 COVID-19 symptoms, which is scored from 0-33 [26] . Participants were also administered 163 the Lawton-Brody Instrumental Activities of Daily Living Scale (IADL) which measures increasing difficulty with practical aspects of everyday functioning on a scale of 0-8 [27] , and the 165 11-item Chalder Fatigue Scale (CFS-11), which measures the severity of both mental and 166 physical fatigue and is scored from 0-33. A cutoff score of >21 is considered clinically 167 significant fatigue [28] . Serological samples were obtained from a subset of participants and 168 assayed for CRP, IL-6, and TNF-α, as elevated levels of these specific proinflammatory markers 169 have been associated with neurocognitive and psychiatric disorders [29] . Assays were performed 170 by the Mayo Clinic Laboratories, and standardized reference ranges were used (Normal = CRP, 171 ≤ 8.0 mg/L; IL-6 ≤ 1.8 pg/ml; for TNF-α ≤ 2.8 pg/ml). 172

Psychiatric measures included pre-COVID-19 psychiatric and substance use disorder 173 (SUD) history, current psychiatric medication use and self-report questionnaires to assess current 174 psychiatric symptoms and disorders. Self-report questionnaires included the Patient Health 175

Questionnaire-9 (PHQ-9), which queries DSM-IV major depression criteria and has a maximum Pearson correlations were used to explore associations between immune markers and clinical 220 variables. Logistic Regression was used to identify independent predictors of extremely low NP 221 test scores, using PAOF memory, language and cognition scores, as well as medical and 222 psychiatric variables that differed between clinical and non-clinical groups as predictors. 223

The participants had a mean age of 41 years, approximately 67% were female, 75% were 226 White or Hispanic, 67% were in a relationship and 75% were employed. On average, participants 227 had a college level education. (Table 1) . 228

From a medical standpoint (Table 2) , the participants had acute COVID-19 illness on 229 average 7 months prior to assessment. The most prevalent acute symptoms were fatigue (92%), 230 respiratory symptoms (90%), neurological symptoms (87%), anosmia (67%) and 231 memory/cognitive problems (57%). Seven participants had been hospitalized for complications 232 of COVID-19, 6 of them reported respiratory distress, 5 cognitive problems or weakness and 3 233 flu-like symptoms. None were admitted to intensive care or required ventilator support. Aside 234 from COVID-19, participants reported on average 1.5 comorbid medical comorbidities, 235 including obesity (25%), asthma (23%), hypertension (17%), sleep apnea (15%), hypothyroidism 236 (15%), migraines (10%), diabetes (7%) and hyperlipidemia (5%). Reported acute versus current 237 COVID-19 symptoms declined, however, half of participants reported current clinically 238 significant fatigue as measured by the CFS. Fifty participants underwent serological testing for 239 IL-6, CRP and TNF-α ( (Tables 2 and 3) . 295

To determine which clinical factors might predict extremely low NP scores, we 297 conducted logistic regression analysis, with extremely low NP scores (≤2 nd percentile) as the 298 dependent variable. Independent variables included acute COVID-19 symptoms, current 299 COVID-19 symptoms, PHQ-9 score, CFS score, number of medical comorbidities and PAOF 300 memory, language and cognition scores . Inflammatory markers were not included in this model 301 as the smaller N would limit predictive power. In the regression model, peak COVID-19 302 symptoms, PHQ-9, number of medical comorbidities and PAOF memory, language and 303 cognition scores were significant predictors of extremely low NP scores, correctly categorizing 304 78% (12/16, p = 0.004). 305 306

Because of the limited number of inflammatory marker results, we calculated Pearson 308 correlation coefficients (r) to explore associations between IL-6, TNF-α and CRP and medical, 309 psychiatric, and neuropsychological variables of interest. IL-6 was significantly correlated with 310 acute COVID illness score (r = 0.32, p < 0.05), number of medical comorbidities (r = 0.58, p < 311 0.001), CFS (r = -0.42, p < 0.01), Stroop Color Word Test t-Score (r = -0.38, p < 0.02 and Trail 312

Making Test Part B (r = 0.30, p<0.05). CRP was correlated with current COVID illness score (r 313 = 0.38, p < 0.01), PHQ-9 score (r=0.32, p<0.05) and inversely correlated with Endicott QLESQ 314 (r = -0.32, p < 0.05). TNF-α had no statistically significant correlations. 315

Data from this sample suggest that individuals reporting cognitive complaints months 317 after acute COVID-19 may indeed have extremely low NP test performance (scored ≤ 2 nd %ile) 318 relative to those without such symptoms. These cognitive difficulties may lead such individuals 319 to seek treatment. When comparing a clinical sample of individuals seeking care for cognitive 320 complaints and other post-COVID symptoms, we found diminished performance in multiple 321 neurocognitive domains relative to age-and education-adjusted norms that were not present in 322 the non-clinical group, including attention, processing speed, memory and executive function. A 323 significantly higher proportion of these individuals had extremely low NP scores. This pattern 324 and degree of performance difficulty is like that documented in prior studies of COVID-19 with 325 smaller sample sizes and shorter timeframe after acute illness, particularly among those who 326 were hospitalized [6, 23-25]. We also found that the Clinical Group had high levels of clinically 327 significant depression and fatigue, diminished quality of life and more limitations in IADLs 328 compared to the Non-Clinical Group, even after covarying for age and medical comorbidity. 329

This suggests that group differences were both statistically and clinically significant, affecting 330 function and quality of life and that these clinical symptoms or their combination appear to lead 331 individuals to seek treatment. 332

The inclusion of a measure of subjective neurocognitive complaints (the PAOF) allowed 333 for investigation of whether perceived impairment correlates with actual impairment. It is 334 important to note that prior studies have found subjective cognitive complaints do not correlate 335 reliably with neuropsychological test impairment [42], leading to skepticism about whether 336 subjective complaints are "real." However, the current data suggests that perception of cognitive 337 problems, even months after acute COVID 19, may be a reliable sign of actual cognitive 338 difficulty and should be investigated. It could be argued that 38% with extremely low NP test 339 performance in a sample of individuals with cognitive complaints is relatively low, that 340 conversely 62% were in the normal range. Nonetheless, the significant differences found in the 341 Clinical Group on individual neuropsychological tests relative to published norms may indicate 342 that individuals with cognitive complaints may be detecting a decline in NP function relative to 343 what would be considered normal for their age and premorbid functioning. J o u r n a l P r e -p r o o f 

SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in 456 a Case of COVID-19 Encephalitis

Structural basis of receptor recognition by SARS-CoV-2. 459

Structural basis for the recognition of SARS-CoV-2 by full-461 length human ACE2

Systematic SARS-CoV-2 screening in cerebrospinal 469 fluid during the COVID-19 pandemic

Viral neuroinvasion and neurotropism without 472 neuronal damage in the hACE2 mouse model of COVID-19. medRXiv

Cognitive 475 impairment after covid-19-a review on Objective Test Data

Long-term neurological manifestations of 478 COVID-19: prevalence and predictive factors. medRXiv

Neurological and cognitive sequelae of Covid-481 19: a four month follow-up

Persistent neurologic symptoms and cognitive 484 dysfunction in non-hospitalized Covid-19 "long haulers

The Lawton Instrumental Activities of Daily Living Scale. AJN

The Chalder Fatigue Scale (CFQ 11)

Inflammation in psychiatric disorders: What comes 494 first?

Quality of Life Enjoyment and Satisfaction 499 Questionnaire